Richard Burr: “Why would you exclude gainful employment from the evaluation of not-for-profit institutions which is what the President…”

I urge my colleagues, don't make this mistake. I know there is great pressure to do Build Back Better. But this is not the right bill.

More than 278 therapies have been approved under the accelerated approval pathway over the 30 year history, saving and improving thousands of lives.

Without Orrin, we wouldn't have a generic drug industry.

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.